IMNM

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Wall Street analysts forecast IMNM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNM is 23.57 USD with a low forecast of 18.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Immunome Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Immunome Inc. EPS for the last quarter amounts to -0.65 USD, decreased -16.67 % YoY.

Immunome Inc (IMNM) has 118 emplpoyees as of December 15 2025.

Today IMNM has the market capitalization of 1.79B USD.